Engflag

Dexatrol

Quick links to important sections

Dexatrol

Dexatrol_ES

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexatrol

Quick Facts

Property Description
Active Ingredients Dexamethasone, Neomycin, Polymyxin B
Form Ophthalmic/Otic Solution, Suspension, or Ointment
Pharmacological Class Ophthalmic Steroids with Anti-infectives
Common Use Managing external inflammation and bacterial presence
Origin Synthetic Glucocorticoid and Semi-synthetic Antibiotics

What Type of Medicine is Dexatrol?

Dexatrol is classified as a prescription-only combination formulation within the Ophthalmic Steroids with Anti-infectives pharmacological class, designed for targeted topical use on the eye or ear. This drug entity is supplied primarily as a sterile ophthalmic solution or suspension. The triple-ingredient composition of Dexamethasone, Neomycin, and Polymyxin B is a well-established formulation, clinically recognized for its synergistic ability to manage external inflammation associated with bacterial involvement, differentiating it from single-agent steroid drops or simple antibiotic solutions.

The Dual Action Composition of Dexatrol

The medicine's unique action stems from its three active components. Dexamethasone is a potent synthetic glucocorticoid known for its anti-inflammatory properties. Corticosteroids like Dexamethasone are used to reduce symptomatic inflammation and related reactions. The antibacterial components include Neomycin, an aminoglycoside antibiotic, and Polymyxin B, a polypeptide antibiotic, which together provide broad-spectrum antibacterial activity. The inclusion of two distinct antibiotic classes, rather than one, is intended to provide coverage against a wider range of bacterial pathogens typically associated with external ear and eye conditions.

General Purpose: Anti-inflammatory and Anti-infective Relief

The general purpose of Dexatrol is to provide relief by managing conditions characterized by both significant inflammation and the presence of susceptible bacterial organisms. The combination is engineered to simultaneously calm symptomatic swelling and redness via the corticosteroid component while actively working to address bacterial proliferation with the dual antibiotic system. This combination is specifically used to manage inflammation in the presence of bacterial infection, providing a comprehensive approach where both swelling and microbial activity are addressed.

Regulatory References

  1. EMA Endorses Dexamethasone Use
  2. Neomycin; Polymyxin B; Dexamethasone Ointment (DailyMed)

What side effects are possible with Dexatrol?

Possible Side Effects and Safety Information

The official safety profile for the Dexamethasone, Neomycin, and Polymyxin B combination is defined by adverse reactions classified under Eye Disorders, Immune System Disorders, and Endocrine Disorders in regulatory documentation.

Local reactions are the most frequently documented adverse effects. Effects such as keratitis, eye irritation, ocular discomfort, and eye pruritus (itching) are classified as uncommon, meaning they occur in 0.1% to 1% of patients according to the regulatory frequency framework.

Serious and Duration-Related Safety Concerns

The use of the corticosteroid component is associated with serious risks, particularly with prolonged use. Regulatory documents explicitly link long-term exposure to the potential development of Glaucoma (ocular hypertension with possible optic nerve damage) and Posterior Subcapsular Cataract formation. The exact incidence for these serious adverse reactions is often listed as not known in official labeling.

Serious, rare systemic reactions are also documented, including the potential for Anaphylaxis and, in cases of intensive or long-term continuous therapy, systemic effects like Cushing's syndrome or Adrenal Suppression may occur due to absorption.

Safety limitations include the risk of globe perforation in eyes with thinning of the cornea or sclera. Furthermore, Pediatric Patients require specific monitoring as the risk of corticosteroid-induced ocular hypertension may be greater and occur earlier than in adults, as explicitly stated in product labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this topical combination (Dexamethasone, Neomycin, Polymyxin B) emphasizes that systemic toxicity is not anticipated following acute, excessive topical application. This is due to the minimal quantity of active ingredients in the ophthalmic or otic solution.

Overdose manifestations primarily involve local ocular toxicity resulting from over-application or misuse. Documented local effects cited in regulatory materials include punctate keratitis, eye irritation, and erythema. For acute topical excess, the official action is often to flush the affected area with lukewarm water and discontinue treatment immediately.

Urgent medical attention is required if the medication is accidentally swallowed (ingested). In such cases, official guidelines mandate that users seek emergency medical assistance or contact a poison control center without delay. Symptomatic and supportive treatment is the defined management approach, as no specific antidote is known.

Regulators also note that the risk of serious long-term systemic outcomes, such as adrenal suppression and Cushing's syndrome, is associated with the intensive or prolonged use of the corticosteroid component in excess of labeled dosing, particularly in susceptible populations like children.

Therapeutic Uses of Dexatrol

What Dexatrol Treats: Main Uses and Benefits

This combination is generally used across conditions presenting with inflammatory or irritative processes in the eye, for which a corticosteroid is considered relevant, and where a bacterial presence or risk is involved. It is applied in addressing symptoms such as redness, swelling, and irritation.

It is used in situations involving symptoms where a combination of inflammation and bacterial presence is identified.

The primary uses include steroid-responsive inflammation of the external ocular structures, post-surgical inflammation, and addressing symptoms following corneal injury from chemical burns or foreign bodies, as well as certain conditions involving persistent inflammation like chronic anterior uveitis. The combination provides support in managing the overall symptom burden during these episodes. It is relevant when short-term symptomatic application is needed.

Quick Fact: Symptomatic Support for Inflammatory and Bacterial Conditions

Property Description
Symptom Focus Redness, swelling, irritation, and discomfort
Condition Context Inflammatory conditions with confirmed or high risk of bacterial presence
Use Scenario Relevant scenarios include post-injury care, postoperative support, and acute infectious episodes
Primary Benefit Provides support to manage the overall symptom load and maintain comfort

Regulatory References

  1. NIH DailyMed Drug Labeling

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

This section outlines the population-specific eligibility rules for the Dexamethasone, Neomycin, and Polymyxin B ophthalmic combination, strictly based on regulatory documents from agencies like the FDA.

Population Status Regulatory Rule
Allowed Populations Adults and older adults are permitted for use. Safety and effectiveness are considered established with no overall differences noted for the geriatric population. Children 2 years of age and older are also considered eligible.
Not Established Use Safety and effectiveness have not been established for use in children younger than 2 years of age.

Absolute Prohibitions (Contraindications)

Dexatrol must not be used in individuals with:

  • Ocular Infection: Epithelial Herpes Simplex Keratitis (dendritic keratitis), Vaccinia, Varicella, or most other viral diseases of the cornea and conjunctiva.
  • Other Infections: Mycobacterial infection of the eye or Fungal diseases of ocular structures.
  • Hypersensitivity: Known or suspected allergy to Dexamethasone, Neomycin, Polymyxin B, or any other component.

Conditional and Restricted Use

Use is considered conditional or requires special caution in specific patient states:

  • Pregnancy: The medicine is Pregnancy Category C and should be used only if the potential benefit justifies the potential risk to the embryo or fetus.
  • Ocular Conditions: Patients with Glaucoma, thinning of the cornea or sclera, or acute purulent conditions must use the medicine with caution and often require monitoring.

These official regulatory statements define the boundaries for use, classifying patients as either eligible, conditionally allowed, or absolutely prohibited from receiving this medication.

What should I know about interactions with other medicines?

Dexatrol’s interaction profile is officially documented based on the low-level systemic absorption of its active components, defining two primary risk categories.

Exposure-Modifying Metabolic Interactions

Co-administration with potent CYP3A4 inhibitors is officially documented to increase the systemic plasma exposure of the Dexamethasone component. This exposure modification carries a regulatory warning regarding the potential risk of systemic effects, such as Cushing’s syndrome or adrenal suppression, particularly when intensive or long-term topical therapy is employed. This risk is noted to be heightened in predisposed patients, including children, when strong inhibitors like Ritonavir or Cobicistat are used.

Additive Pharmacodynamic Interactions

Caution is required when using this medicine concomitantly with systemic, oral, or other topical drugs that are known to possess neurotoxic, ototoxic, or nephrotoxic effects. This combination of agents may result in additive toxicity due to the recognized properties of the Neomycin and Polymyxin B antibiotic components. Official regulatory documents advise that co-administration with such agents should be avoided when possible.

Local Administration Timing Rules

When administering other topical ophthalmic preparations, a mandatory time separation is required. This constraint prevents the local washout of the active ingredients, ensuring the intended local concentration is maintained.

Mechanism of Action

How Dexatrol Works: The Mechanism of Action

Dexatrol exerts its primary effect by acting as an agonist of the Glucocorticoid Receptor ( GR), an intracellular transcription factor present in most cells. This binding initiates a molecular cascade where the activated drug-receptor complex moves into the nucleus, leading to the modulation of gene expression.

The primary molecular mechanism is transrepression, where the complex suppresses the activity of key pro-inflammatory transcription factors, such as Nuclear Factor Kappa B ( NF-kappa B). This action blocks the synthesis of numerous inflammatory mediators, including cytokines ( IL-6, TNF-alpha), which limits the activity of pro-inflammatory signaling pathways.

A second crucial step involves increasing the expression of the protein Lipocortin-1. This protein indirectly inhibits the enzyme Phospholipase A2 ( PLA2), preventing the formation of inflammatory signaling molecules like prostaglandins and leukotrienes from the Arachidonic Acid Cascade. The cascade disruption limits the extravasation and activity of immune cells and the related changes in vascular permeability.

Beyond immune influence, the drug's mechanism also affects metabolic systems by promoting gluconeogenesis and protein breakdown, mimicking the effects of the body's natural stress hormones. This action contributes to the widespread systemic physiological changes associated with the drug's effect profile.

Dosage and Administration Information

How to Use Dexatrol

Dexatrol is administered through the topical ophthalmic route only, and it is supplied as a sterile suspension (drops) and a sterile ointment. The frequency of use is dependent on the clinical context; standard adult dosing ranges from a starting regimen of one to two drops four to six times daily for mild inflammation, up to hourly for severe initial episodes. For the ointment form, a small 0.5-inch ribbon is typically applied to the affected conjunctival sac.

The administration schedule for both forms is designed to be tapered, meaning the frequency is gradually decreased as the clinical condition improves, and the treatment duration is intended for short-term use. If there is no clinical improvement after two days, re-evaluation is typically indicated. The suspension is shaken well immediately before use to ensure proper drug distribution.

Specific procedural conditions ensure correct delivery. If other topical eye products are required, they are spaced by at least five minutes to minimize drug washout. Furthermore, soft contact lenses are removed prior to application of the suspension due to the preservative agent, and they should only be reinserted after 15 minutes. The adult dosing schedule for the drops is generally applied to children aged two years and older, though the safety and efficacy of the ointment have not been established in younger pediatric populations.

Recent Clinical Evidence

Dexatrol: Recent Clinical Evidence

️ Evidence for Use in Ocular Inflammation and Bacterial Risk

Research exploring the combination of Dexamethasone, Neomycin, and Polymyxin B has been applied in controlled clinical evaluations, including Randomized Controlled Trials (RCTs), focused on conditions characterized by irritation and swelling in the external eye where a bacterial component was evaluated concurrently. Studies primarily monitored outcomes related to physical discomfort and outcomes linked to inflammatory states, tracking changes in redness and irritation, as well as bacterial clearance. Researchers rigorously monitored eye pressure changes, a key outcome measured in studies due to the corticosteroid component. The research describes a focus on short-term symptom changes and acute episodes, and the evidence is limited in duration.

Evidence for Use in Postoperative Care

This combination was studied for research scenarios involving adult patients recovering from specific surgical procedures, such as cataract surgery. The research, which included controlled, multi-center trials, explored the dual purpose of monitoring post-surgical inflammation and investigating infectious complications. Studies monitored outcomes related to systemic or functional imbalance, tracking inflammatory markers and evaluating visual function. Findings describe patterns observed regarding the measured changes in inflammation in the immediate post-surgical phase. Comparative evidence against every single-agent alternative remains lacking in some areas.

Research Gaps and Limitations

The follow-up durations were limited in most research, reflecting the drug’s intended short-term use, meaning long-term effects are not fully established. Clinical research was studied for populations including adults and children aged 2 years and older, but data for certain groups remain insufficient. A key area of scientific uncertainty noted in regulatory reviews is the potential for the corticosteroid component to influence the presentation of non-bacterial infections, highlighting a research gap.

Key Studies & References NIH DailyMed Drug Labeling for Dexamethasone / Neomycin / Polymyxin B Ophthalmic Solution

Frequently Asked Questions (FAQ)

Common questions about Dexatrol (FAQ)

Q: What is Dexatrol used for?

A: Dexatrol is a medication that has been authorized for specific indications. It is primarily used in the management of certain conditions where modulating specific biological pathways may be beneficial, as determined by a healthcare provider.

Q: How is Dexatrol thought to work?

A: Research suggests that Dexatrol primarily interacts with cellular receptors, which may influence subsequent signaling cascades. This mechanism of action is currently under study to fully understand its therapeutic relevance.

Q: What do clinical studies say about Dexatrol's effectiveness?

A: Clinical trial evidence suggests that some participants receiving Dexatrol have experienced measurable changes in their condition markers compared to placebo groups. The extent of this observation can vary, and further research is ongoing to characterize its role in long-term management.

Q: Is Dexatrol associated with any side effects?

A: As with all medications, Dexatrol has been studied for its potential adverse effects. Common observations include minor gastrointestinal changes and temporary fatigue. Not all individuals experience these effects.

How should Dexatrol be stored and disposed of?

How to Store and Dispose of Dexatrol?

Official labeling mandates specific conditions to maintain the stability and sterility of this medicine.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 8 C to 25 C (46 F to 77 F). Do not freeze.
Protection Keep the container tightly closed and protect the medicine from light, moisture, and excessive heat.
Post-Opening Life The medicine must be discarded after 28 days following the first opening of the container.
Child Safety Store the product out of the sight and reach of children.

Disposal Instructions

Disposal of unused, unwanted, or expired product must be done according to local requirements. The medicine must not be poured into wastewater systems like the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dexatrol found in:

A-Z Index: